KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Income: 2014-2024

Historic Operating Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$466.6 million.

  • CRISPR Therapeutics AG's Operating Income fell 19.91% to -$132.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$574.4 million, marking a year-over-year decrease of 72.81%. This contributed to the annual value of -$466.6 million for FY2024, which is 109.66% down from last year.
  • CRISPR Therapeutics AG's Operating Income amounted to -$466.6 million in FY2024, which was down 109.66% from -$222.5 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Operating Income registered a high of $373.5 million during FY2021, and its lowest value of -$673.2 million during FY2022.
  • Moreover, its 3-year median value for Operating Income was -$466.6 million (2024), whereas its average is -$454.1 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Operating Income tumbled by 858.31% in 2020 and then spiked by 205.39% in 2021.
  • Over the past 5 years, CRISPR Therapeutics AG's Operating Income (Yearly) stood at -$354.4 million in 2020, then soared by 205.39% to $373.5 million in 2021, then slumped by 280.22% to -$673.2 million in 2022, then skyrocketed by 66.94% to -$222.5 million in 2023, then tumbled by 109.66% to -$466.6 million in 2024.